SIGN UP
LOG IN
MARKET
OKYO
OKYO
OKYO PHARMA LTD
NASDAQ
1.440
+0.030
+2.13%
Opening 11:28 04/18 EDT
OPEN
1.380
PREV CLOSE
1.410
HIGH
1.450
LOW
1.380
VOLUME
6.73K
TURNOVER
0
52 WEEK HIGH
3.250
52 WEEK LOW
0.9201
MARKET CAP
47.86M
P/E (TTM)
-0.0023
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at OKYO last week (0408-0412)?
Weekly Report · 3d ago
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease. OKYO is rescheduling a Key Opinion Leader event scheduled for April 2024 to May 2024. The Company plans to present at upcoming ophthalmic conferences.
Forward News · 04/08 23:00
Weekly Report: what happened at OKYO last week (0401-0405)?
Weekly Report · 04/08 11:15
OKYO PHARMA ANNOUNCES UPCOMING PRESENTATION OF OK-101 PHASE 2 DATA FOR DRY EYE DISEASE AT EYECELERATOR 2024, A PARTNER MEETING OF THE AMERICAN SOCIETY FOR CATARACT AND REFRACTIVE SURGERY
Reuters · 04/02 11:00
Weekly Report: what happened at OKYO last week (0325-0329)?
Weekly Report · 04/01 11:13
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Landos Biopharma, Inc. Shares jumped 171.2% to $21.70 on Monday. AbbVie and Landos signed a definitive agreement to acquire the company. Altamira Therapeutics Ltd. Shares climbed 70.1% after falling around 22% on Friday. GameStop Corp. Shares rose 8.4% after the company announced a separation.
Benzinga · 03/25 18:44
Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack
On the Move Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack. Etao International down 96% on account of reverse stock split and share restructure announced last week. Bitcoin Depot down 11% on Q4 earnings release.
Seeking Alpha · 03/25 12:41
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Salarius Pharmaceuticals, Inc. Shares rose sharply in pre-market trading following fourth-quarter results. The company posted a net loss of $0.9 million for the fourth quarter. Canopy Growth Corporation and Esperion Therapeutics were among the other stocks moving in the day's trading.
Benzinga · 03/25 12:03
About OKYO
OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.
Webull offers OKYO Pharma Ltd stock information, including NASDAQ: OKYO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OKYO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading OKYO stock methods without spending real money on the virtual paper trading platform.